Research Paper Volume 15, Issue 9 pp 3644—3677
FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma
Figure 6. FAM46C was related to LDH level and clinical therapy in in multiple myeloma patients. (A) The comparison of clinical information between FAM46C-low and FAM46C-high group. (B) FAM46C was related to bortezomib and dexamethasone therapy in multiple myeloma patients. Left, bortezomib, P = 0.03, Chi-square test, two sided. Right, dexamethasone, P = 0.048, Chi-square test, two sided.